First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology.

ABSTRACT: Recent advances in understanding the mechanisms of nonsmall cell lung cancer (NSCLC) has led to the development of targeted treatments, including the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib, and the irreversible ErbB family blocker afatinib. Several important activating EGFR mutations have now been identified, which correlate strongly with response to treatment with these agents. Multiple randomised controlled trials have confirmed the association between the presence of activating EGFR mutations and objective response to gefitinib, erlotinib and afatinib, thus demonstrating their superiority over platinum-based chemotherapy as first-line treatment for NSCLC patients with EGFR mutation-positive tumours, and resulting in approval

SUBMITTER: Sebastian M 

PROVIDER: S-EPMC9487257 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature